NSE:SUVEN (India)
Â
Shs Dematerialsed
₹
307.1
+7.85 (+2.62%)
Jul 31
Business Description
Suven Life Sciences Ltd
ISIN : INE495B01038
Share Class Description:
NSE:SUVEN: Shs DematerialsedTotal Employee Number:
187Compare
Compare
Traded in other countries / regions
530239.India IPO Date
2003-10-23Description
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.32 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 155.85 | |||||
Beneish M-Score | 0.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.5 | |||||
3-Year EBITDA Growth Rate | -32.5 | |||||
3-Year EPS without NRI Growth Rate | -21.5 | |||||
3-Year FCF Growth Rate | -35.2 | |||||
3-Year Book Growth Rate | 9.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.21 | |||||
9-Day RSI | 45.59 | |||||
14-Day RSI | 49 | |||||
3-1 Month Momentum % | 32.46 | |||||
6-1 Month Momentum % | 111.32 | |||||
12-1 Month Momentum % | 3.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 29.15 | |||||
Quick Ratio | 29.15 | |||||
Cash Ratio | 10.08 | |||||
Days Sales Outstanding | 66.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.5 | |||||
Shareholder Yield % | -8.94 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -4077.7 | |||||
Net Margin % | -3884.13 | |||||
EBITDA Margin % | -3803.01 | |||||
FCF Margin % | -4307.95 | |||||
OCF Margin % | -4236.5 | |||||
ROE % | -84.37 | |||||
ROA % | -75.59 | |||||
ROIC % | -138.08 | |||||
3-Year ROIIC % | -125.89 | |||||
ROC (Joel Greenblatt) % | -150.82 | |||||
ROCE % | -82.84 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 960.19 | |||||
PB Ratio | 13.66 | |||||
Price-to-Tangible-Book | 13.66 | |||||
EV-to-EBIT | -30.71 | |||||
EV-to-EBITDA | -31.35 | |||||
EV-to-Revenue | 1192.27 | |||||
EV-to-FCF | -27.68 | |||||
Price-to-GF-Value | 3.15 | |||||
| Price-to-Net-Current-Asset-Value | 15.72 | |||||
| Price-to-Net-Cash | 51.7 | |||||
Earnings Yield (Greenblatt) % | -3.26 | |||||
FCF Yield % | -3.54 | |||||
Forward Rate of Return (Yacktman) % | -30.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Suven Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 71.147 | ||
| EPS (TTM) (₹) | -12.41 | ||
| Beta | 1.6975 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 2.49 | ||
| Volatility % | 80.66 | ||
| 14-Day RSI | 49 | ||
| 14-Day ATR (₹) | 18.43249 | ||
| 20-Day SMA (₹) | 327.1625 | ||
| 12-1 Month Momentum % | 3.04 | ||
| 52-Week Range (₹) | 124.11 - 371 | ||
| Shares Outstanding (Mil) | 282.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Suven Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Suven Life Sciences Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 2:1 Stock Split | 2007-03-23 | 0.43 (-2.03%) |
Show
Entries
Suven Life Sciences Ltd Frequently Asked Questions
What is Suven Life Sciences Ltd(NSE:SUVEN)'s stock price today?
The current price of NSE:SUVEN is ₹307.10. The 52 week high of NSE:SUVEN is ₹371.00 and 52 week low is ₹124.11.
When is next earnings date of Suven Life Sciences Ltd(NSE:SUVEN)?
The next earnings date of Suven Life Sciences Ltd(NSE:SUVEN) is .
Does Suven Life Sciences Ltd(NSE:SUVEN) pay dividends? If so, how much?
Suven Life Sciences Ltd(NSE:SUVEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Suven Life Sciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers